The average one-year price target for Aligos Therapeutics (NasdaqCM:ALGS) has been revised to $67.12 / share. This is an increase of 70.91% from the prior estimate of $39.27 dated April 12, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $20.20 to a high of $183.75 / share. The average price target represents an increase of 943.79% from the latest reported closing price of $6.43 / share.
What is the Fund Sentiment?
There are 41 funds or institutions reporting positions in Aligos Therapeutics. This is an decrease of 3 owner(s) or 6.82% in the last quarter. Average portfolio weight of all funds dedicated to ALGS is 0.02%, an increase of 34.04%. Total shares owned by institutions increased in the last three months by 5.56% to 2,801K shares.
What are Other Shareholders Doing?
Deep Track Capital holds 444K shares representing 8.24% ownership of the company. No change in the last quarter.
Alyeska Investment Group holds 412K shares representing 7.65% ownership of the company. No change in the last quarter.
Sio Capital Management holds 336K shares representing 6.24% ownership of the company. No change in the last quarter.
Woodline Partners holds 289K shares representing 5.37% ownership of the company. In its prior filing, the firm reported owning 468K shares , representing a decrease of 61.91%. The firm decreased its portfolio allocation in ALGS by 51.65% over the last quarter.
Marshall Wace, Llp holds 269K shares representing 4.99% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
